Treatment of primary central nervous system lymphoma

doi:10.3760/cma.j.issn.1673-422X.2016.01.020

Abstract

Abstract: As a kind of rare central nervous system malignant tumor, primary central nervous system lymphoma (PCNSL) has poor prognosis, and the main treatment include surgery, radiotherapy and chemotherapy. Stereotactic biopsy has become a routine diagnostic method of PCNSL, because of which has the advantage of minimally invasive and convenient. Whole brain radiotherapy is a standardized treatment method for the multifocal PCNSL, which can delay the progress of tumor in a short term. The therapeutic regimen based on high dose methotrexate leads to significant changes in the PCNSL treatment and it has become an effective treatment measure. Effective comprehensive treatment is the key to extending survival time and improving the quality of life for the patients with PCNSL.

Key words: Lymphoma, Central nervous system neoplasms, Radiotherapy, Drug therapy, Methotrexate

Li Xiaoyou, Feng Jifeng. Treatment of primary central nervous system lymphoma[J]. Journal of International Oncology, 2016, 43(1): 71-74.

References

［1］ Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma［J］. Curr Treat Options Oncol, 2013, 14(4): 539-552. DOI:10.1007/s11864-013-0252-6. ［2］ Korfel A, Schlegel U. Primary CNS lymphoma. Progress in the diagnostics and therapy［J］. Nervenarzt, 2015, 86(6): 710715. DOI:10.1007/s00115-014-4227-z. ［3］朴颖哲, 李鹏, 刘群, 等. 原发性中枢神经系统淋巴瘤23例临床分析［J］. 中华内科杂志, 2011, 50(11): 954-957. DOI:10.3760/cma.j.issn.0578-1426.2011.11.013. ［4］ Joerger M, Huitema AD, Krhenbühl S, et al. Methotrexate area under the curve with is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokineticpharmacodynamic analysis from the IELSG no.20 trial［J］. Br J Cancer, 2010, 102(4): 673-677. DOI:10.1038/sj.bjc.6605559. ［5］ Thiel E, Korfel A, Martus P, et al. Highdose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (GPCNSLSG1): a phase 3, randomised, noninferiority trial［J］. Lancet Oncol, 2010, 11(11): 1036-1047. DOI:10.1016/S1470-2045(10)70229-1. ［6］ Kadoch C, Li J, Wong VS, et al. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma［J］. Clin Cancer Res, 2014, 20(4): 10291041. DOI:10.1158/1078-0432.CCR-13-0474. ［7］ Xu G, Yang M, Tong H, et al. Highdose methotrexate plus temozolomide as a salvage treatment in metastatic central nervous system lymphoma: two cases report and review of literature［J］. Int J Clin Exp Med, 2015, 8(5): 8222-8225. ［8］ Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brian lymphomas［J］. Br J Cancer, 2007, 96(6): 864-867. DOI:10.1038/sj.bjc.6603660. ［9］ Kurzwelly D, Glas M, Roth P, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status［J］. J Neurooncol, 2010, 97(3): 389-392. DOI:10.1007/s11060-009-0032-0. ［10］ Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas［J］. Cancer, 2004, 101(1): 139-145. DOI:10.1002/cncr.20339. ［11］ Ishiura Y, Shiba Y, Ikeda H, et al. Analysis of factors associated with the quality of life in patients with nonsmall cell lung cancer who received outpatient pemetrexed maintenance therapy［J］. Gan To Kagaku Ryoho, 2014, 41(6): 761-764. ［12］ Wang Y, Wang X, Zhao Y, et al. Curative effect of pemetrexed on the treatment of relapsed primary central nervous system lymphoma［J］. Zhonghua Xue Ye Xue Za Zhi, 2014, 35(1): 46-49. DOI:10.3760/cma.j.issn.0253-2727.2014.01.012. ［13］ Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma［J］. Cancer, 2012, 118(15): 3743-3748. DOI:10.1002/cncr.26709. ［14］王勇, 刘保岩, 许德志, 等. 17例复发性原发中枢神经系统淋巴瘤的临床观察［J］. 临床肿瘤学杂志, 2013, 18(4): 364-367. ［15］ Illerhaus G, Müller F, Feuerhake F, et al. Highdose chemotherapy and autologous stemcell transplantation without consolidating radiotherapy as firstline treatment for primary lymphoma of the central nervous system［J］. Haematologica, 2008, 93(1): 147-148. DOI:10.3324/haematol.11771. ［16］ Colombat P, Lemevel A, Bertrand P, et al. Highdose chemotherapy with autologous stem cell transplantation as firstline therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group［J］. Bone Marrow Transplant, 2006, 38(6): 417-420. DOI:10.1038/sj.bmt.1705452. ［17］陆晓林, 朱海燕, 靖彧, 等. 自体造血干细胞移植治疗原发中枢神经系统淋巴瘤2例并文献复习［J］. 临床荟萃, 2014, 29(6): 640-643. DOI:10.3769/j.issn.1004583X.2014.06.013. ［18］ Riganti C, Salaroglio IC, PinzònDaza ML, et al. Temozolomide downregulates Pglycoprotein in human bloodbrain barrier cells by disrupting Wnt3 signaling［J］. Cell Mol Life Sci, 2014, 71(3): 499-516. DOI:10.1007/s00018-013-1397-y. ［19］ Attia SM. Molecular cytogenetic evaluation of the aneugenic effects of teniposide in somatic and germinal cells of male mice［J］. Mutagenesis, 2012, 27(1): 31-39. DOI:10.1093/mutage/ger051. ［20］ Wu JJ, Wang XH, Li L, et al. Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma［J］. Asian Pac J Cancer Prev, 2014, 15(11): 4733-4738. ［21］ Bernard S, Goldwirt L, Amorim S, et al. Activity with ibrutinib in mantle cell lymphoma patients with central nervous system relapse［J］. Blood, 2015, 126（14）： 1695-1698. DOI:10.1182/blood-2015-05-647834. ［22］ Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma［J］. Neurology, 2015, 84(3): 325-326. DOI:10.1212/WNL.0000000000001158.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[15]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.